Michael P Dube (VP, Chief Accounting Officer) sold ~$23K of Intellia Therapeutics
Automatic saleLoading…
Intellia Therapeutics
NTLA · NASDAQ · In Vitro & In Vivo Diagnostic Substances
NTLA · NASDAQ · In Vitro & In Vivo Diagnostic Substances
In Vitro & In Vivo Diagnostic Substances company based in Cambridge, Ma.
In the last 90 days, no insider of Intellia Therapeutics reported an open-market purchase and 1 open-market sale worth about $23K. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 6, 2026
$12.37
Last 12 months
Not enough history
Market value
Not available
Bets against the stock: 46.7M shares sold short, +6.3% vs the previous count, 14.1 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Revenue
$7.66M
−46.2% vs the same quarter a year earlier
Free cash flow, last 12 months
−$349M
This quarter −$84.9M, a year earlier −$99.9M
Net debt
—
Debt —, cash $106M, at Jun 30, 2026
Net income, last 12 months
−$400M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 6, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
1 sale
$23K sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Michael P Dube (VP, Chief Accounting Officer) sold ~$23K of Intellia Therapeutics
Automatic saleEliana Clark (Officer) plans to sell ~$736K of Intellia Therapeutics
Planned, from payPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
3 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in hereditary angioedema, neuromuscular disease, transthyretin amyloidosis (attr) with cardiomyopathy. The ones with the nearest registered primary completion date still ahead:
2 trials have a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.